FDA to hasten review of Immunomedics' pancreatic cancer drug

02/5/2009 | Forbes

Immunomedics' yttrium-90-labeled hPAM4, a treatment for pancreatic cancer, obtained fast-track designation from the FDA. The drug is undergoing early-stage clinical development.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT